الهيئة العامة للغذاء والدواء
Saudi Food & Drug Authority

Saudi Public Assessment Report

(Summary Report)

Posacore®

Type of Application: New drug application.

Type of Product: Human generic drug.

Active Pharmaceutical Ingredient(s): Posaconazole.

ATC code: J02AC04.

Dosage Form: Prolonged-release tablet.

Dosage Strength: 100 mg.

Pack Size: 24.

Shelf life: 24 months.

Storage Conditions: Gastro-resistant tablet.

Reference Product in SA (if applicable): NOXAFIL 100 mg. Prolonged-release tablet.

Marketing Authorization Holder: Innovative Healthcare Solutions Co.

Manufacturer: Haimen pharma Inc.

Registration No.: 2308222535.

Date of Decision: Approved on 9/08/2022.

Proposed Indications:

Indicated for use in the treatment of the following fungal infections in adults:

- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products.
- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B.
- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole.
- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.

Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

Posacore tablets are also indicated for prophylaxis of invasive fungal infections in the following patients:

- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high-risk of developing invasive fungal infections.
- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.

Please refer to the Summary of Product Characteristics (SPC) of Posaconazole oral suspension for use in oropharyngeal candidiasis.

Product Background

This product is considered as a human generic drug, for Saudi regulatory purposes. Furthermore, this product is qualified to follow the SFDA's regulatory pathway regular submission.

The SFDA approval for Posacore® (POSACONAZOLE 100 mg) is based on a review of the quality, safety and efficacy as summarised hereinafter:

Quality Aspects

Drug Substance

- Posaconazole is a white to off-white crystalline powder. Posaconazole is freely soluble in dichloromethane, dimethyl sulfoxide and N-Methyl-2-pyrrolidone, slightly soluble in acetonitrile, sparingly. Soluble in methanol and acetone, very slightly soluble in ethanol and isopropanol. Posaconazole does have four chiral center. Polymorphism has been observed (Form-I).
- The drug substance (DS) is manufactured by a multiple-step chemical synthesis.
- The structure of Posaconazole has been fully elucidated using several spectroscopic techniques.
- The drug substance specification includes relevant tests for proper quality control. The control methods are validated according to international guidelines.
- Appropriate stability data have been presented and justify the established re-test period.

Drug Product

- The finished product is available as a yellow, coated and oblong tablets, debossed with "100" on one side. Each coated tablet contains 100 mg of Posaconazole. The composition of the drug product is adequately described, qualitatively and quantitatively. Suitable pharmaceutical development data have been provided for the finished product composition and manufacturing process.
- The manufacturing process is described narratively and in sufficient detail, taking into account pharmaceutical development data. Batch manufacturing formulas and in-process controls are included. The drug product (DP) specification covers appropriate parameters for this dosage form which allow for proper control of the finished drug product. The control methods are validated according to international guidelines. Batch data show consistent quality of the drug product.

- The drug product is packaged in a carton box, containing 2 PCTFE/PVC film blister pack with aluminum foil with protective layer and adhesive layer (25µm, 253mm), each blister contains 12 tablets.
- Appropriate stability data have been generated in the packaging material intended for commercial use and following relevant international guidelines. The data show good stability of the finished product and support the shelf life.

Clinical Aspects

Bioequivalence Study

Bioequivalence study under fasting conditions:
Ratio and 90% Confidence Intervals (CI) of Posacore® (Posaconazole) 100 mg versus Noxafil® (Posaconazole) 100 mg:

Pharmacokinetic Parameter	**Point Estimate**	**90% CI**
C_{max} (ng/mL)	101.45	91.62 – 112.33
AUC_{0-t} (ng/mL)	104.84	95.89 – 114.63
$AUC_{0-\infty}$ (ng/mL)	104.74	95.83 – 114.47

Bioequivalence study under fed conditions:
Ratio and 90% Confidence Intervals (CI) of Posacore® (Posaconazole) 100 mg versus Noxafil® (Posaconazole) 100 mg:

Pharmacokinetic Parameter	**Point Estimate**	**90% CI**
C_{max} (ng/mL)	99.84	96.57 – 103.22
AUC_{0-t} (ng/mL)	100.12	97.34 – 102.97
$AUC_{0-\infty}$ (ng/mL)	100.30	97.34 – 103.35

Based on the results obtained in these studies, Posacore® (Posaconazole) 100 mg of Haimen Pharma Inc., China, is **bioequivalent** to Noxafil® (Posaconazole) 100 mg of N.V. Organon, Oss, The Netherlands, under fasting and fed conditions.

Product Information

The approved Summary of Product Characteristics (SPC) with the submission can be found in Saudi Drug Information System (SDI) at: https://sdi.sfda.gov.sa/

The date of revision of this text corresponds to that of the Saudi PAR. New information concerning the authorized medicinal product in question will not be incorporated into the Saudi PAR. New findings that could impair the medicinal product's quality, efficacy, or safety are recorded and published at (SDI or Summary Saudi-PAR report).

For inquiry and feedback regarding Saudi PAR, please contact us at Saudi.PAR@sdfa.gov.sa